

REMARKS

New claims 79-98 are presented for consideration

Claim 79 is based on original claims 2, 11, 13, 22 as well as on the specification (English text on page 2, l. 8-14; page 12, l. 23-30).

Claims 80 and 81 are directed to preferred peptide analogues.

Claims 82-91 correspond to original claims 7, 10, 12 and 14-20, respectively.

Claim 92 is based on original claims 21-23 and 32 as well as on the specification (English text on page 2, l. 8-14; page 12, l. 23-30).

Claims 93 and 94 are directed to preferred peptide analogues.

Claims 95-98 correspond to original claims 28, 31, 33 and 34, respectively.

A table explaining the different meanings of substituents A1 to A8 and Z (and supporting claims 79 and 92), is attached to this paper.

The new claims are believed by Applicants to be patentable over the Hirai et al. (US 4,659,696) and Mehlem (US 2003/0162721) references.

Accordingly, Applicants urge the Examiner to favorably reconsider the pending rejections under 35 USC 102(b) and 35

USC 103(a), in the light of the amended claims.

It is believed by the Applicants that the present application is now in condition for allowance and early notice of such action is earnestly solicited. If any final points remain that can be clarified by telephone, Examiner Desai is respectfully encouraged to contact Applicants' attorney at the number indicated below.

Applicants hereby petition the Commissioner for Patents to extend the time for reply to the final Office Action dated October 19, 2005, for three (3) months from January 19, 2006, to April 19, 2006. A duly completed credit card authorization form is attached to effect payment of the extension fee.

Respectfully submitted



Malcolm J. MacDonald
Reg. No. 40,250
Tel: (703) 837-9600 Ex. 24